Revised Scoping Document

PDF cover

Asthma: Revised Scoping Document

The proposed scope for ICER’s initial draft report on mepolizumab (Nucala, GlaxoSmithKline plc.) for the treatment of severe eosinophilic asthma. This version of the scope incorporates feedback from a one week public comment period.


View All Materials on this Topic or Go Back to View More Materials